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Introduction
Polycystic ovary syndrome (PCOS) is a common endocrine 
disease linked with metabolic complications, and insu-
lin resistance (IR) plays an important role in the develop-
ment and persistence of this disorder [1]. The gold stand-
ard for directly measuring insulin sensitivity in humans is 
the hyperinsulinemic euglycemic glucose clamp, but it is 
time consuming, labor intensive, expensive and technically 
demanding [2]. The homeostatic model assessment of IR 
(HOMA-IR) is the main method for IR measurement used 
in scientific studies because it is a simple and noninvasive 
[3]. Due to the relevance of IR in the setting of PCOS, it 
would be important for both research and clinical applica-
tion to identify additional biochemical parameters that may 
help in identifying IR.
PCOS and insulin resistance
Polycystic ovary syndrome (PCOS) is the most common 
endocrine disorder affecting 10–15 % of women in repro-
ductive age. The etiology of the disease is still not totally 
understood, and the clinical presentation is extremely vari-
able but generally includes clinical or biochemical hyper-
androgenism, menstrual disorders (oligo-amenorrhea) and 
polycystic ovaries on ultrasound.
In the last years, specific diagnostic criteria were devel-
oped to allow the diagnosis of PCOS. In 1990 were estab-
lished the criteria of the National Institute of Health (NIH), 
followed by ESHRE/ASRM (European Society of Human 
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common endocrine-metabolic disorder in women of repro-
ductive age. The diagnostic criteria include two out of 
three features: hyperandrogenism, polycystic ovaries on 
ultrasound and menstrual irregularities (Rotterdam Crite-
ria 2003). PCOS patients are more vulnerable to develop 
diabetes, cardiovascular diseases and metabolic syndrome. 
Insulin resistance (IR) is prevalent in women with PCOS 
independently of obesity and is critically involved in repro-
ductive and metabolic complications of the syndrome. Sev-
eral tests have been developed to measure IR, some very 
reliable but complex like the hyperinsulinemic euglyce-
mic glucose clamp and others less precise but easier and 
less invasive like HOMA-IR. New markers are needed to 
reach a more reliable assessment of insulin resistance. To 
date, several surrogate markers have been proposed in the 
literature to facilitate and improve the determination of 
IR. Many new proteins are strongly involved with PCOS 
physiopathology and IR, such as some adipocytokines 
(adiponectin, visfatin, vaspin and apelin), copeptin, irisin, 
PAI-1 and zonulin. Many other proteins have been pro-
posed as potential new markers of IR in PCOS, such as 
resistin, leptin, RBP4, kisspetin and ghrelin, but their role 
is still controversial. In this review, we provide a short 
characterization of these new markers, recently studied as 
indicators of metabolic state.
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Reproduction and Embryology/American Society of 
Reproduction Medicine) criteria established in Rotterdam 
in 2003. After exclusion of other diseases, the diagnosis 
of PCOS requires two out of the following three criteria: 
oligo-anovulation, clinical or biochemical androgen excess, 
ultrasound polycystic morphology of at least one ovary (at 
least 12 follicles measuring 2–9 mm in diameter or ovarian 
volume greater than 10 cm3).
In 2011, the Amsterdam ESHRE/ASMR-sponsored 
3rd PCOS Consensus Workshop Group identified differ-
ent PCOS phenotypes, separating the classic phenotype 
(hyperandrogenism and chronic anovulation, with or with-
out PCO) from those with ovulation disorders and polycys-
tic morphology [4].
The clinical phenotypes present different metabolic 
risks, and IR is a hallmark of the classic and the ovulatory 
phenotypes [5]. IR and hyperinsulinemia determine hyper-
androgenemia stimulating ovarian theca cells to secrete 
androgens and increasing LH effect on ovarian androgen 
production. Both androgens and insulin inhibit SHBG 
secretion, increasing free and bioactive androgen levels 
and making clinical androgen excess worse. Moreover, IR 
is critically involved in the development of metabolic syn-
drome and cardiovascular disease in PCOS women, that 
is why its treatment (lifestyle changes, insulin-sensitizing 
drugs and bariatric surgery) is thought to important both to 
decrease IR and to alleviate its consequences [6].
Measuring insulin resistance is neither simple nor neces-
sarily accurate. This is why several tests have been devel-
oped to quantify this metabolic phenomenon. Some of 
these tests are very reliable but complex, while others are 
less precise but more readily usable in clinical research due 
to simplicity and reduced invasiveness. Hyperinsulinemic 
euglycemic glucose clamp is the gold standard for directly 
determining metabolic insulin sensitivity. It consists in a 
constant insulin infusion resulting in a new steady-state 
insulin level above the fasting level that enhances glucose 
disposal in skeletal muscle and adipose tissue and inhib-
its hepatic glucose production. 20 % dextrose is given to 
“clamp” blood glucose levels in the euglycemic range. 
This technique directly measures all body glucose disposal 
under steady-state insulin conditions, but it is time consum-
ing, labor intensive, expensive and technically demanding 
[2].
The homeostasis model assessment (HOMA) deter-
mines IR and pancreatic β-cell function from basal glucose 
and insulin (or C-peptide) levels with a simple mathemati-
cally derived nonlinear equation (HOMA-IR: fasting insu-
lin (mU/ml) × fasting glucose (mmol/l)/22.5 (normalizing 
factor)) [3].
The quantitative insulin sensitivity check index 
(QUICKI) is a simple variation of the HOMA equation that 
provides a consistent and accurate insulin sensitivity index 
with positive predictive power and with a significantly bet-
ter correlation with glucose clamp determinations of insu-
lin sensitivity than other simple surrogates [7]. It is easy, 
minimally invasive, inexpensive and commonly used in 
clinical research studies.
The oral glucose tolerance test (OGTT) is a simple test 
widely used in medical practice to identify glucose intoler-
ance or type 2 diabetes. After an oral glucose load (75 g), 
blood glucose and insulin concentrations are determined 
at 0, 30, 60 and 120 min. OGTT provides important infor-
mation about glucose tolerance, but not insulin sensitivity/
resistance per se [8].
The minimal model analysis of the frequently sampled 
intravenous glucose tolerance test (FSIVGTT) is a sim-
ple indirect measurement of insulin sensitivity/resistance. 
Blood samples are taken for 3 h after an intravenous bolus 
of glucose administration followed by an insulin infusion. 
The collected data are analyzed using a computer program 
MINMOD to provide an insulin sensitivity index [9].
Matsuda index is a simple assessment of insulin sensitiv-
ity from the OGTT that provides an excellent approxima-
tion of whole-body insulin sensitivity (WBISI = 10,000/√ 
(fasting glucose × fasting insulin) (mean glucose × mean 
insulin) [10].
New markers: structure, action and role in insulin 
resistance
Although several tests exist to assess insulin resistance, the 
availability of new markers is highly needed, in the aim to 
achieve a more reliable assessment of insulin metabolism. 
To date, a number of new proteins have been proposed as 
surrogate markers for the assessment of insulin resistance. 
Below, we provide a short characterization of markers, 
which have recently been studied as serum/plasma indica-
tors of metabolic state.
Adipocytokines
Adipose tissue is implicated in the secretion of several hor-
mones such as adiponectin, resistin, leptin, visfatin, apelin, 
retinol-binding protein 4 (RBP 4), called adipocytokines, 
that are involved in energy homeostasis and metabolism 
[11].
Adiponectin is secreted exclusively by mature adipo-
cytes. Decreased adiponectin plasma levels are associated 
with insulin resistance [12], obesity, type 2 diabetes mel-
litus and cardiovascular diseases [13]. There are many sci-
entific studies on adiponectin in PCOS patients. Sepilian 
and Nagamani [14] reported a significant negative correla-
tion between serum adiponectin levels and insulin resist-
ance, with no correlation between BMI and adiponectin in 
3J Endocrinol Invest (2017) 40:1–8 
1 3
PCOS patients, suggesting that insulin sensitivity seems to 
be the major determinant of adiponectin levels rather than 
adiposity.
Panidis et al. [15] observed lower serum adiponectin 
levels in PCOS patients with insulin resistance (measured 
by HOMA-IR) than in normal population. Similar find-
ings were observed by Yildiz et al. [16] who demonstrated 
a relationship between increased insulin resistance and 
decreased adiponectin levels, suggesting that it could be an 
adequate marker of insulin resistance and its consequences 
such as diabetes mellitus and metabolic syndrome.
Resistin is an adipose-derived peptide hormone discov-
ered in 2001 that potentially links obesity and diabetes mel-
litus [17]. The role of resistin in insulin resistance of PCOS 
is still controversial. Seow et al. [18] found that hyperin-
sulinemic PCOS patients and controls had similar serum 
resistin levels, but resistin mRNA levels were twofold 
higher in adipocytes from PCOS patients, suggesting a par-
acrine regulation of insulin resistance. Lewandowski et al. 
[19] reported a strong negative correlation between adi-
ponectin and resistin levels in PCOS women during OGTT 
but without a direct correlation with insulin resistance, and 
they speculated that the adiponectin-to-resistin ratio might 
help in predicting the cardiovascular risk in these patients. 
Higher resistin levels were found in PCOS patients by 
Yilmaz et al. [20], but independently from insulin resist-
ance and BMI. Wang et al. [21] observed significantly 
higher resistin levels in obese and non-obese PCOS groups 
than in controls and HOMA-IR had a positive correlation 
with resistin and a negative correlation with adiponectin. 
Conversely, Pangaribuan et al. [22] found that none of the 
24 PCOS patients in their study presented hyperesistine-
mia, there was no significant difference in serum resistin 
concentration between PCOS group and controls, and there 
was no correlation with BMI and HOMA-IR; instead, they 
showed that lower adiponectin level was associated with 
insulin resistance and BMI in PCOS women.
Leptin is a peptide hormone secreted from adipose tis-
sue and plays an important role in food intake and energy 
homeostasis [23]. Insulin stimulates leptin gene expression, 
enhancing leptin secretion [24]. The implication of leptin 
in insulin resistance of PCOS is still unclear. Micić et al. 
[25] found significantly higher leptin levels in obese PCOS 
patients compared with non-obese PCOS women and con-
trols with a negative correlation between insulin sensitiv-
ity and leptin levels in both PCOS groups. Some years 
later, Erturk et al. [26] did not reveal significant correlation 
between leptin and HOMA-IR or hyperinsulinemia, sug-
gesting that leptin levels are related only to obesity. Oppo-
site results were obtained by Pehlivanov and Mitkov [27], 
who showed a positive correlation between serum leptin 
levels and insulin resistance, independently of obesity. One 
possible explanation for this difference is the heterogeneity 
of the patients, who presented the BMI in the upper limit 
of normal values. Recently, similar to Erturk’s study, Nas-
rat et al. [28] found that leptin and BMI were significantly 
correlated without a significant association with insulin 
resistance, but they evaluated only PCOS patients without a 
control group and they did not analyze the molecular mech-
anisms for further validation. Garruti et al. [29] reported 
low leptin levels in serum and in follicular fluid in non-
obese PCOS patients undergoing in vitro fertilization, with 
a significant correlation with BMI and insulinemia.
In 2005, Fukuhara and his group isolated a new adi-
pocytokine called visfatin, which expression increases in 
obesity. Visfatin has an insulin-mimetic effect in mice and 
in vitro reduces plasma glucose levels [30, 31]. Kowalska 
et al. [32] reported lower insulin sensitivity in both lean and 
obese PCOS patients, but increased serum visfatin levels 
only in lean PCOS women with a negative correlation with 
insulin sensitivity and a positive correlation with markers of 
hyperandrogenism, suggesting that obesity may deregulate 
visfatin expression and that other factors may be involved 
in this process. Similar findings in non-obese PCOS sub-
jects were observed by Gen et al. [33], who reported also a 
strong association with total cholesterol, high-density lipo-
protein and markers of hyperandrogenism. Later, in a study 
performed on obese PCOS adolescent girls, Cekmez et al. 
[34] showed a significant enhancement of HOMA-IR and 
visfatin and apelin levels and significantly lower adiponec-
tin levels, speculating that adipocytokines can be used as 
specific markers for insulin resistance. Nevertheless, a 
recent meta-analysis including 1341 patients indicated vis-
fatin levels were significantly elevated in PCOS subjects, 
suggesting that visfatin could be a potential biomarker for 
PCOS, but there was no correlation with insulin resistance, 
BMI and hyperandrogenism [35].
Visceral adipose tissue-derived serine protease inhibitor 
(vaspin) is a novel adipocytokine identified in obese dia-
betic rats, where it improves glucose tolerance and insulin 
sensitivity [36]. In a small case–control study performed by 
Tan et al. [37], obese PCOS women had enhanced vaspin 
mRNA and protein in omental adipose tissue and high 
plasma vaspin levels, which decreased after treatment with 
metformin. Positive associations with HOMA-IR and glu-
cose were found, suggesting that high vaspin levels may be 
a consequence of insulin resistance. Similar results were 
found by Koiou et al. [38]. In their study, serum vaspin lev-
els were higher in both lean and obese PCOS patients than 
in controls. QUICKI was lower in PCOS subjects, suggest-
ing that insulin resistance and obesity enhance vaspin lev-
els. However, treatment with metformin, diet and weight 
loss appeared to not affect serum vaspin concentrations.
Apelin is a peptide isolated from bovine stomachs, but it 
is expressed in several other organs and also in visceral and 
subcutaneous tissues [39]. Apelin was found to be higher 
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in PCOS patients by Gören et al. [40] but without a signifi-
cant correlation with HOMA-IR. Olszanecka-Glinianowicz 
et al. [41] reported an inverse association between apelin 
and glucose, insulin and HOMA-IR values, supporting the 
role of apelin in the regulation of insulin sensitivity. Apelin 
levels were higher in non-obese PCOS patients, suggesting 
a compensatory mechanism for metabolic consequences 
of insulin resistance. Different from Cekmez’s study [34], 
lower serum concentrations of apelin were found in PCOS 
subjects by Altinkaya et al. [42] with positive correlation 
with BMI, insulin, HOMA-IR, triglyceride and free testos-
terone, speculating that apelin can be used as a marker for 
insulin sensitivity. Conversely, Sun et al. [43] observed sig-
nificantly enhanced apelin concentration in PCOS patients 
with positive association with BMI and HOMA-IR; treat-
ment with drospirenone-ethinylestradiol plus metformin 
improved insulin resistance and apelin levels. Discrepant 
findings among the published studies may be attributed 
to the differences in ethnicity, age, study design, sample 
size, genetic characteristics of populations, and assessment 
methodology.
The data concerning serum retinol-binding protein 4 
(RBP4), an adipocytokine involved in systemic insulin 
resistance, are inconclusive. Weiping et al. [44] found ele-
vated RBP4 levels in PCOS patients regardless of obesity 
with negative correlation with insulin sensitivity, suggest-
ing that this protein could be an important link between 
adipose tissue and insulin resistance in PCOS. In line with 
this study, Möhlig et al. [45] observed that elevated RBP4 
levels were significantly associated with insulin resistance. 
RBP4 levels were higher in women suffering from meta-
bolic syndrome or impaired glucose metabolism, but ROC 
curve analysis showed that plasma RBP4 does not appear 
to be a clinically useful parameter to predict metabolic con-
sequences in PCOS women. On the other hand, Hanh et al. 
[46] noted that RBP4 were associated with obesity but not 
with indices of insulin resistance and they found no dif-
ferences in RBP4 concentrations between PCOS patients 
and controls, concluding that its levels are not influenced 
by PCOS per se. No correlation with insulin resistance was 
found also by Hutchison et al. [47], who noted that RBP 
levels did not change after treatment with metformin or oral 
contraceptives, which reduced and enhanced insulin resist-
ance, respectively, concluding that RBP4 cannot be used 
as a marker of insulin resistance in PCOS. Cohort size, the 
choice of methodology for the evaluation of insulin resist-
ance, selection bias or methodological differences in RBP4 
measurements could contribute to obscure this relatively 
small impact on IR observed. Recently, contrarily to pre-
vious studies [45, 46], Olszanecka-Glinianowicz et al. [48] 
reported significantly higher RBP4 levels in normal weight 
PCOS compared to obese PCOS subjects and significantly 
lower concentrations in normal weight controls compared 
to obese controls, with a negative correlation between 
RBP4 and HOMA-IR or insulin concentrations, hypoth-
esizing a compensatory effect in the negative feedback 
between RBP4 and insulin resistance to prevent deteriora-
tion in obese PCOS patients.
Kisspeptin
In the literature, there are limited data about kisspeptin 
changes and hormonal and metabolic diseases. Kisspep-
tin, also called metastin, is a peptide produced by KiSS-1 
gene involved in puberty activation and is the key stimulat-
ing factor of GnRH pulsatile secretion during the ovulation 
[49]. Panidis et al. [50] found lower kisspeptin serum levels 
in PCOS women than in controls, and they reported sig-
nificantly higher kisspeptin levels in normal weight PCOS 
subjects than in overweight or obese women with the dis-
ease with negative correlation with BMI, androgens, fasting 
insulin levels and HOMA-IR, suggesting that insulin resist-
ance is linked to decreased kisspeptin levels. In this study, 
the number of control women was relatively small and no 
lean healthy volunteers were involved. Therefore, it is too 
soon to draw definite conclusions. Different findings were 
reported by Jeon et al. [51] and Yilmaz et al. [52], who 
observed that kisspeptin levels were significantly increased 
in normal weight and obese PCOS women compared with 
controls with positive correlation with androgenic profile 
but without significant association with insulin resistance, 
suggesting that kisspeptin can be used as a specific marker 
for hyperandrogenism in PCOS. Further studies are neces-
sary to elucidate the role of kisspeptin in metabolic conse-
quences in PCOS.
Copeptin
To date, few studies were performed to assess the con-
nection between plasma copeptin levels and metabolic 
risk in PCOS. Saleem et al. [53] performed a multicenter, 
community-based study on 1293 African-Americans and 
1197 non-Hispanic whites to investigate the association of 
copeptin, the C-terminal pro-vasopressin fragment, with 
insulin resistance and presence of metabolic syndrome. In 
both groups, copeptin levels were higher in participants 
with metabolic syndrome with positive correlation with 
insulin levels and HOMA-IR and independent association 
with adiposity and dyslipidemia, suggesting that copeptin 
may be a novel marker of insulin resistance and metabolic 
syndrome. Karbek et al. [54] found enhanced copeptin 
levels in PCOS patients positively associated with fast-
ing insulin, HOMA-IR, androgenic profile, triglycerides 
and carotid intima media thickness, indicating that copep-
tin may play an important role in cardiometabolic con-
sequences in PCOS. Similar findings were observed by 
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Taskin et al. [55], who reported that enhanced copeptin 
levels in obese PCOS women were associated with insulin 
resistance and obesity.
Irisin
Irisin is a novel myokine recently identified in humans 
and mice involved in brown-fat-like development of white 
fat, energy expenditure, weight loss and improved glucose 
tolerance [56]. The relationship between irisin and insulin 
resistance is still not totally elucidated, and the regulation 
of this myokine has yet to be demonstrated. Li et al. [57] 
demonstrated that irisin levels were significantly higher 
in PCOS subjects than in controls and in overweight and 
obese patients than in lean women in both groups. Sig-
nificant positive correlation between circulating irisin with 
insulin resistance and dyslipidemia was found. They stud-
ied the effect of hyperinsulinemia on irisin levels with the 
hyperinsulinemic euglycemic glucose clamp: At the begin-
ning of the assay, short-term hyperinsulinemia determined 
a rapid decrease of irisin concentrations in both groups, and 
therefore, during the steady state of the test, its levels were 
constant, suggesting that elevated irisin concentrations in 
PCOS patients may be a consequence of metabolic stress. 
After metformin therapy, authors observed significantly 
decreased irisin levels and improved insulin resistance in 
PCOS women. Recently, similar results were obtained by 
Li et al. [58], who noted significantly increased irisin lev-
els in overweight and obese PCOS women with high free 
androgen index (FAI) with an evident increase in insulin 
resistance and hyperandrogenemia, suggesting that elevated 
irisin levels predict insulin resistance, metabolic syndrome 
and hyperandrogenemia.
Ghrelin
Ghrelin is a multifunctional peptide hormone secreted 
principally in the stomach. It stimulates several biological 
functions including food intake, glucose release, cell pro-
liferation and reproduction [59]. The first study assessing 
the relationship between ghrelin levels and insulin resist-
ance in PCOS was performed by Schöfl et al. [60], who 
compared PCOS women with healthy controls and gastrec-
tomized subjects. In this study, ghrelin levels were lower 
in insulin-resistant patients and were similar to the levels 
found in gastrectomized women; in insulin-sensitive PCOS 
patients, ghrelin concentration was comparable to controls. 
A significant correlation between ghrelin levels and insulin 
resistance was found in PCOS women; treatment with met-
formin improved insulin sensitivity and enhanced serum 
ghrelin levels, suggesting that its reduction in PCOS may 
be a cause or a consequence of insulin resistance. Lower 
ghrelin levels in PCOS patients were also found by Mitkov 
et al. [61], with a strong negative association with clinical 
and hormonal indices of insulin resistance. These data are 
in conflict with Houjeghani’s et al. [62] results, who did 
not observe significant difference in ghrelin concentration 
between PCOS patients and control group, without cor-
relation with BMI and insulin resistance. Similar results 
were obtained recently by Cassar et al. [63], who reported 
that ghrelin and other biomarkers were strongly correlated 
with obesity rather than PCOS per se and that only PAI-1 
may be a predictor of insulin resistance independently of 
PCOS status. This discrepancy of results may be explained 
by confounding factors, such as body weight, fat mass, age, 
hormonal status, and severity of disease. Ghrelin may play 
an important role in the development of PCOS and meta-
bolic consequences, but to date too much heterogeneity 
was identified and further studies are necessary to establish 
the exact relationship between ghrelin levels and PCOS.
PAI‑1
Plasminogen activator inhibitor-1 (PAI-1), a glycopro-
tein involved in the coagulation system, seems to play an 
important role in PCOS and in its metabolic consequences. 
Sampson et al. [64] reported increased PAI-1 serum con-
centrations in non-obese PCOS patients with a significant 
strong association with hyperinsulinemia. Similar findings 
were observed by Orio et al. [65] and Tarkun et al. [66], 
suggesting that increased PAI-1 levels may be a predictor 
factor in cardiovascular risk in PCOS women. Recently, as 
mentioned before, Cassar et al. [67] found that PAI-1 was 
the only biomarker linked to insulin resistance in PCOS 
subject, with high accuracy to predict IR (>70 %), while 
other biomarkers investigated in the study (ghrelin, visfatin, 
leptin, C-protein) were more strongly correlated with BMI 
rather than PCOS status.
Zonulin
Zonulin is a novel eukaryotic protein that reversibly regu-
lates gut permeability opening intestinal tight junctions and 
seems involved in the pathogenesis of autoimmune diseases 
[67]. The association between zonulin and metabolic disor-
ders has been recently recognized. Moreno-Navarrete et al. 
[68] investigated the relationship between this protein and 
obesity and insulin resistance, and they found that zonu-
lin levels appear to be significantly increased in obese and 
glucose-intolerant subjects with a positive correlation with 
insulin resistance and inflammatory markers such as IL-6. 
To date, there is only one study that investigates serum 
zonulin levels in PCOS patients. Zhang et al. [69] reported 
significantly elevated zonulin levels in women with the dis-
ease compared to controls and demonstrated a strong cor-
relation with insulin resistance, obesity, dyslipidemia and 
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severity of menstrual disorders, speculating that increased 
gut permeability may alter the intestinal barrier determin-
ing an inflammatory state that leads to insulin resistance. 
Further studies are necessary to confirm the role of zonulin 
and alterations of intestinal permeability in the physiopa-
thology of PCOS.
Conclusions
With this article, we provide a short characterization of 
a variety of methods used for the determination of insulin 
resistance/sensitivity in PCOS patients. The gold stand-
ard for direct measurement of insulin sensitivity is the 
hyperinsulinemic euglycemic glucose clamp technique, 
but HOMA-IR and QUICKI are the most used methods in 
the scientific literature [3, 7]. Many new proteins are now 
surfacing as potential new markers of insulin resistance in 
PCOS. In the scientific literature, we found a strong connec-
tion between adipocytokines (in particular adiponectin, vis-
fatin, vaspin and apelin), copeptin, irisin, PAI-1 and zonulin 
with insulin resistance and PCOS physiopathology, while 
the role of other proteins (such as resistin, leptin, RBP4, 
kisspetin and ghrelin) is still controversial. Many scientific 
articles tried to use surrogate markers to simplify the assess-
ment of insulin resistance, anticipate the diagnosis of meta-
bolic and cardiovascular consequences in PCOS, improve 
the use of medical resources, and reduce costs and side 
effect. Further studies are necessary to better clarify the role 
of these proteins with insulin resistance in this syndrome.
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